Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296805 | 0.86 | SSTR5 (0.41) | RAB9ANPC1SSTR5KCNH2 | |
| SCHEMBL18344137 | 0.84 | NPC1 (0.43) | RAB9ANPC1 | |
| SCHEMBL20296520 | 0.78 | MGLL (0.46) | RAB9ANPC1 | |
| SCHEMBL29364368 | 0.78 | MAPT (0.45) | RAB9ANPC1MEN1KMT2AADORA2A | |
| SCHEMBL20296756 | 0.78 | ADORA2A (0.42) | ADORA2AADORA1CRHR1SYKADRA1A | |
| SCHEMBL24824337 | 0.78 | TLR7 (0.46) | RAB9ANPC1MEN1KMT2AADORA2A | |
| SCHEMBL20296328 | 0.78 | RAB9A (0.52) | RAB9A | |
| SCHEMBL29113595 | 0.78 | TLR7 (0.46) | RAB9ANPC1MEN1KMT2AADORA2A | |
| SCHEMBL30097204 | 0.76 | CHRNA7 (0.43) | RAB9ANPC1KMT2AADORA2AADORA1 | |
| SCHEMBL18344136 | 0.76 | SYK (0.40) | ADORA2AADORA1CRHR1SYKADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584118-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-10 | — | — | US | disclosed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584118-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | RAB9A 2128/4885NPC1 3120/4885MEN1 4875/4885 |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | RAB9A 2128/4885NPC1 3120/4885MEN1 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.